NO2718319T3 - - Google Patents
Info
- Publication number
- NO2718319T3 NO2718319T3 NO12727062A NO12727062A NO2718319T3 NO 2718319 T3 NO2718319 T3 NO 2718319T3 NO 12727062 A NO12727062 A NO 12727062A NO 12727062 A NO12727062 A NO 12727062A NO 2718319 T3 NO2718319 T3 NO 2718319T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Physiology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494134P | 2011-06-07 | 2011-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2718319T3 true NO2718319T3 (cg-RX-API-DMAC10.html) | 2018-05-05 |
Family
ID=46246296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO12727062A NO2718319T3 (cg-RX-API-DMAC10.html) | 2011-06-07 | 2012-06-06 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US20120315255A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP2718319B1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2836921C (cg-RX-API-DMAC10.html) |
| ES (2) | ES2774491T3 (cg-RX-API-DMAC10.html) |
| NO (1) | NO2718319T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2012170531A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2718319T3 (cg-RX-API-DMAC10.html) * | 2011-06-07 | 2018-05-05 | ||
| WO2013143698A1 (en) * | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules |
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| JP6989262B2 (ja) | 2014-10-27 | 2022-01-05 | アセコー インコーポレイテッド | 皮下外来患者管理 |
| EP3337402B1 (en) | 2015-08-20 | 2026-01-07 | Glytec, LLC | Diabetes management therapy advisor |
| WO2020025357A1 (en) * | 2018-08-02 | 2020-02-06 | Novozymes A/S | Preparation of combinatorial libraries of dna constructs using introns |
| CN120349985A (zh) * | 2018-10-12 | 2025-07-22 | 建新公司 | 通过肝导向基因替代疗法治疗严重pku的改良的人pah的产生 |
| CN113939595A (zh) | 2019-06-07 | 2022-01-14 | 瑞泽恩制药公司 | 包括人源化白蛋白基因座的非人动物 |
| TW202302858A (zh) * | 2021-03-16 | 2023-01-16 | 威斯康辛校友研究基金會 | 治療糖尿病之胰島素基因療法 |
| CA3252672A1 (en) * | 2022-05-09 | 2023-11-16 | Endsulin, Inc. | VARIANT OF PREPROINSULIN AND CONSTRUCTIONS FOR INSULIN EXPRESSION AND THE TREATMENT OF DIABETES |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5427940A (en) | 1991-06-03 | 1995-06-27 | Board Of Regents, The University Of Texas System | Engineered cells producing insulin in response to glucose |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| US5534404A (en) | 1993-12-10 | 1996-07-09 | Cytotherapeutics, Inc. | Glucose responsive insulin secreting β-cell lines and method for producing same |
| US7425443B2 (en) | 1997-01-21 | 2008-09-16 | Wisconsin Alumni Research Foundation | Treatment of diabetes with synthetic beta cells |
| US6352857B1 (en) | 1997-01-21 | 2002-03-05 | Wisconsin Alumni Research Foundation | Treatment of diabetes with synthetic beta cells |
| US8021875B2 (en) * | 2001-08-27 | 2011-09-20 | Roche Madison Inc. | Methods for expression of transgenes |
| WO2007127408A2 (en) | 2006-04-28 | 2007-11-08 | Tulane University Health Sciences Center | Methods for treating diabetes |
| DE102008042352A1 (de) | 2008-09-25 | 2010-04-08 | Robert Bosch Gmbh | Ansteuerung eines Synchrongleichrichters |
| NO2718319T3 (cg-RX-API-DMAC10.html) * | 2011-06-07 | 2018-05-05 |
-
2012
- 2012-06-06 NO NO12727062A patent/NO2718319T3/no unknown
- 2012-06-06 CA CA2836921A patent/CA2836921C/en active Active
- 2012-06-06 ES ES17198106T patent/ES2774491T3/es active Active
- 2012-06-06 WO PCT/US2012/041099 patent/WO2012170531A1/en not_active Ceased
- 2012-06-06 EP EP12727062.7A patent/EP2718319B1/en active Active
- 2012-06-06 US US13/490,081 patent/US20120315255A1/en not_active Abandoned
- 2012-06-06 EP EP17198106.1A patent/EP3293197B1/en active Active
- 2012-06-06 ES ES12727062.7T patent/ES2658487T3/es active Active
-
2013
- 2013-12-18 US US14/133,016 patent/US9732356B2/en active Active
-
2017
- 2017-08-10 US US15/673,938 patent/US10443072B2/en active Active
-
2019
- 2019-08-30 US US16/556,552 patent/US20190382791A1/en not_active Abandoned
-
2021
- 2021-08-16 US US17/403,138 patent/US12163147B2/en active Active
-
2024
- 2024-11-12 US US18/944,753 patent/US20260117250A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012170531A1 (en) | 2012-12-13 |
| US20140170123A1 (en) | 2014-06-19 |
| ES2774491T3 (es) | 2020-07-21 |
| US20260117250A1 (en) | 2026-04-30 |
| EP2718319A1 (en) | 2014-04-16 |
| US10443072B2 (en) | 2019-10-15 |
| US20190382791A1 (en) | 2019-12-19 |
| ES2658487T3 (es) | 2018-03-12 |
| EP2718319B1 (en) | 2017-12-06 |
| US12163147B2 (en) | 2024-12-10 |
| CA2836921C (en) | 2020-08-18 |
| US20120315255A1 (en) | 2012-12-13 |
| EP3293197A1 (en) | 2018-03-14 |
| EP3293197B1 (en) | 2020-01-08 |
| US9732356B2 (en) | 2017-08-15 |
| CA2836921A1 (en) | 2012-12-13 |
| US20210388381A1 (en) | 2021-12-16 |
| US20170342441A1 (en) | 2017-11-30 |